Crinetics Pharmaceuticals Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Gayathri Diwakar - Head of Investor Relations Scott Struthers - Founder and Chief Executive Officer Dana Pizzuti - Chief Medical and Development Officer Jim Hassard - Chief Commercial Officer Marc Wilson - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Jessica Fye - JPMorgan Yasmeen Rahimi - Piper Sandler Jeff Hung - Morgan Stanley Dennis Ding - Jefferies Joseph Schwartz - Leerink Partners Gavin Clark-Gartner - Evercore ISI Charles Moore - Baird Catherine Novack - Jones Research Jon Wolleben - Citizens JMP Leland Gershell - Oppenheimer Douglas Tsao - H.C. Wainwright Cory Jubinville - LifeSci Capital Operator Good day everyone, and welcome to the Crinetics Pharmaceuticals Second Quarter 2024 Earnings Conference Call.
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.94 per share a year ago.
Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Crinetics Pharmaceuticals (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
